We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have added about 2% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak reported fourth-quarter 2025 loss of $1.04 per share, wider than the Zacks Consensus Estimate of $1.02 per share. The company had incurred a loss of 84 cents per share in the year-ago quarter.
The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues.
KOD's Q4 Results in Detail
Research and development expenses were $45.5 million in the reported quarter, up 43.1% year over year. The rise was mainly due to increased clinical activities associated with ongoing clinical studies and higher stock-based compensation expenses.
General and administrative expenses were $12 million, down 17% year over year, primarily due to lower non-cash stock-based compensation expenses and additional sublease income offsetting costs.
As of Dec. 31, 2025, Kodiak had cash, cash equivalents and marketable securities worth $209.9 million compared with $72 million as of Sept. 30, 2025.
Full-Year 2025 Results
For full-year 2025, the company incurred a net loss of $4.32 per share, wider than a loss of $3.35 per share incurred in 2024.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -7.58% due to these changes.
VGM Scores
Currently, Kodiak Sciences has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Kodiak Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD - Free Report) . Shares have added about 2% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak reported fourth-quarter 2025 loss of $1.04 per share, wider than the Zacks Consensus Estimate of $1.02 per share. The company had incurred a loss of 84 cents per share in the year-ago quarter.
The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues.
KOD's Q4 Results in Detail
Research and development expenses were $45.5 million in the reported quarter, up 43.1% year over year. The rise was mainly due to increased clinical activities associated with ongoing clinical studies and higher stock-based compensation expenses.
General and administrative expenses were $12 million, down 17% year over year, primarily due to lower non-cash stock-based compensation expenses and additional sublease income offsetting costs.
As of Dec. 31, 2025, Kodiak had cash, cash equivalents and marketable securities worth $209.9 million compared with $72 million as of Sept. 30, 2025.
Full-Year 2025 Results
For full-year 2025, the company incurred a net loss of $4.32 per share, wider than a loss of $3.35 per share incurred in 2024.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -7.58% due to these changes.
VGM Scores
Currently, Kodiak Sciences has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Kodiak Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.